Evidence map›Paper›PMID 29796302›Full record

ReviewFuture science OA2018

Prospective single center trial of next-generation sequencing analysis in metastatic renal cell cancer: the MORE-TRIAL.

Svenja Dieffenbacher, Stefanie Zschäbitz, Luisa Hofer, Gencay Hatiboglu, Weibin Hou, Markus Hohenfellner, Stefan Duensing, Holger Sültmann, Sascha Pahernik, Carsten Grüllich

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Future science OA, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Svenja DieffenbacherThe Renal Cancer Center at the National Center for Tumor Diseases (NCT) Heidelberg, Germany, Department of Urology, Heidelberg University Hospital, Im Neuenheimer Feld 110, Heidelberg, Germany.
Stefanie ZschäbitzThe Renal Cancer Center at the National Center for Tumor Diseases (NCT) Heidelberg, Germany, Department of Medical Oncology, National Center for Tumor Diseases Heidelberg, Heidelberg University Hospital, Im Neuenheimer Feld 460, Heidelberg, Germany.
Luisa HoferThe Renal Cancer Center at the National Center for Tumor Diseases (NCT) Heidelberg, Germany, Department of Urology, Heidelberg University Hospital, Im Neuenheimer Feld 110, Heidelberg, Germany.
Gencay HatibogluThe Renal Cancer Center at the National Center for Tumor Diseases (NCT) Heidelberg, Germany, Department of Urology, Heidelberg University Hospital, Im Neuenheimer Feld 110, Heidelberg, Germany.
Weibin HouThe Renal Cancer Center at the National Center for Tumor Diseases (NCT) Heidelberg, Germany, Section of Molecular Uro-oncology, Department of Urology, Heidelberg University Hospital, Im Neuenheimer Feld 110, Heidelberg, Germany.
Markus HohenfellnerThe Renal Cancer Center at the National Center for Tumor Diseases (NCT) Heidelberg, Germany, Department of Urology, Heidelberg University Hospital, Im Neuenheimer Feld 110, Heidelberg, Germany.
Stefan DuensingThe Renal Cancer Center at the National Center for Tumor Diseases (NCT) Heidelberg, Germany, Section of Molecular Uro-oncology, Department of Urology, Heidelberg University Hospital, Im Neuenheimer Feld 110, Heidelberg, Germany.
Holger SültmannThe Renal Cancer Center at the National Center for Tumor Diseases (NCT) Heidelberg, Germany, Cancer Genome Research Group, German Cancer Consortium (DKTK), Heidelberg, Germany, German Cancer Research Center (DKFZ) & National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Sascha PahernikThe Renal Cancer Center at the National Center for Tumor Diseases (NCT) Heidelberg, Germany, Department of Urology, Nuremberg General Hospital, Paracelsus Medical University, Nuremberg, Germany.
Carsten GrüllichThe Renal Cancer Center at the National Center for Tumor Diseases (NCT) Heidelberg, Germany, Department of Urology, Heidelberg University Hospital, Im Neuenheimer Feld 110, Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTargeted therapies have substantially improved the survival of patients with metastatic clear cell renal cell cancer. No prognostic or predictive biomarkers are available. Comprehensive genetic profiling offers the opportunity to define prognostic and predictive signatures aiming at a more personalized approach to treatment.

methodsIn this prospectively conducted cohort study, tumor tissue and liquid biopsies are sampled at baseline and upon first and second progression under systemic treatment. Samples will be analyzed by whole-exome sequencing to generate prognostic and predictive patterns for systemic therapies. DISCUSSION: This study is aiming at exploring genetic profiles with prognostic and predictive value in metastatic renal cell cancer patients. Clonal evolution facilitating resistance to systemic treatment will be investigated by repeat biopsies.

Indexed as

clonal evolutionnext-generation sequencingrenal cell carcinomatargeted therapytumor heterogeneity

Identifiers

PMID29796302
PMCPMC5961447

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.